() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Emerald Health Therapeutics

Emerald Health Pharmaceuticals Receives U.S. Drug Enforcement Administration Determination that the Active Ingredient in its Lead Product Candidate is not a Controlled Substance

April 17, 2019 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, has received the determination from the United States Drug Enforcement Administration (DEA) that VCE-004.8, a non-reactive, non-psychotropic, new chemical entity (NCE) derived from synthetic cannabidiol (CBD)  and the active pharmaceutical ingredient (API) in the Company’s lead product candidate, EHP-101, is not a controlled substance under the Controlled Substance Act (CSA). EHP-101 is currently in a Phase I clinical study and is being developed for the treatment of multiple sclerosis (MS) and systemic scleroderma, or systemic sclerosis (SSc).
Read more